Welcome to our dedicated page for Alpine Immune Sc news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpine Immune Sc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpine Immune Sc's position in the market.
Frazier Life Sciences (FLS) has appointed Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. Dr. Gold, previously Co-Founder, CEO, and Executive Chairman of Alpine Immune Sciences (ALPN), led the company from inception to its recent $4.9 billion acquisition by Vertex Pharmaceuticals in May 2024. He also founded Alpine Biosciences, which was sold to Cascadian Therapeutics in 2014.
Dr. Peng joins FLS from his role as President and Head of Research and Development at Alpine Immune Sciences, where he led the development of multiple drug candidates, including povetacicept. His experience includes leadership positions at Seagen, Roche, and Stemcentrx. Both appointments aim to strengthen FLS's capabilities in identifying and developing breakthrough biopharmaceutical companies.
Alpine Immune Sciences reported its financial results for the first quarter of 2024, with a cash position of $362.4 million. Vertex Pharmaceuticals will acquire Alpine for $65 per share, expected to close in Q2 2024. Collaboration revenue decreased to $7.0 million, with an increase in research and development expenses to $22.5 million. Net loss for Q1 2024 was $17.9 million.
FAQ
What is the current stock price of Alpine Immune Sc (ALPN)?
What is the market cap of Alpine Immune Sc (ALPN)?
